Statement by Chip Davis, President and CEO, GPhA, Regarding the 21st Century Cures Act
Contact: Steve Arnoff
Chip Davis, President and CEO, GPhA
“We congratulate Chairman Upton, Ranking Member Pallone, Representative DeGette, Chairman Alexander and Ranking Member Murray on the release of the final draft of the 21st Century Cures Act. GPhA recognizes this bill is a bipartisan achievement that should spur innovation and benefit patients. Notably, the package includes important funding to support the Comprehensive Addiction and Recovery (CARA) Act which will help address the public health crisis surrounding prescription drug abuse. We urge Congress to expeditiously pass this bill.
While the 21st Century Cures Act released today does not include provisions GPhA supports to increase prescription drug pricing competition, we will continue working with Congress to find solutions to rising drug costs that bring safe and effective generic drugs to market more quickly and ensure more patients and payers have access to them. Towards that end, GPhA will continue to support and seek enactment of the bi-partisan CREATES Act sponsored by Senators Grassley, Lee, Leahy, and Klobuchar and the FAST Generics Act sponsored by Representatives Stivers and Welch. “
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 89 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.